Tiagabine
| Clinical data | |
|---|---|
| Pronunciation | /taɪˈæɡəbiːn/ |
| Trade names | Gabitril |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a698014 |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 90–95% |
| Protein binding | 96% |
| Metabolism | Hepatic (CYP450 system, primarily CYP3A) |
| Onset of action | Tmax = 45 min |
| Elimination half-life | 5–8 hours |
| Excretion | Fecal (63%) and renal (25%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H25NO2S2 |
| Molar mass | 375.55 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Tiagabine, sold under the brand name Gabitril, is an anticonvulsant medication produced by Cephalon that is used in the treatment of epilepsy. The drug is also used off-label in the treatment of anxiety disorders including panic disorder.